IP
ABCL icon

Intellectus Partners’s AbCellera Biologics ABCL Stock Holding History

Intellectus Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$185K – 272
2021
Q3 		$185K Buy
100,000
+32,800
+49% +$580K 0.04% 261
2021
Q2 		$189K Buy
+67,200
New +$1.85M 0.04% 259

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Intellectus Partners's ABCL Position: Q2 2026 in Review

Intellectus Partners increased its AbCellera Biologics (ABCL) stake by 1% in Q2 2026, buying an estimated $26.9K and bringing the position to 551,583 shares worth $4.33M. The position accounts for 0.75% of the portfolio, ranked #26.

Intellectus Partners first reported a position in ABCL in Q2 2021 and has held it in 21 quarters since. The position peaked at $26.6M in Q2 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Intellectus Partners held 551,583 shares of AbCellera Biologics worth $4.33M as of Q2 2026.
  • Intellectus Partners bought 5,500 AbCellera Biologics shares in Q2 2026, an estimated $26.9K.
  • AbCellera Biologics made up 0.75% of Intellectus Partners's portfolio in Q2 2026, its #26 holding.
  • Intellectus Partners first reported a position in AbCellera Biologics in Q2 2021 and has held it in 21 quarters since.
  • Intellectus Partners's AbCellera Biologics position peaked at $26.6M in Q2 2021.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.